United States Patent 9,603,806: Scope, Claim Set, and Landscape Impact
United States Patent 9,603,806 covers a two-part capsule for H. pylori therapy that combines: (i) an immediate-release antibiotic in the form of compressed minitablets, and (ii) a delayed-release proton pump inhibitor (PPI) also in compressed minitablets with a coating and basket dissolution thresholds that define an acid-to-buffer release transition.
The claim core is not “omeprazole + antibiotic in one capsule.” It is the specific physical format (compressed minitablets in a capsule) paired with a two-stage dissolution profile for the PPI that limits PPI release in acid and then forces release in phosphate buffer, plus downstream dependent claim features that extend to time-delay agents, typical API selections and ratios, and dosing regimen and eradication performance.
What is the independent claim scope (Claim 1) and what does it legally lock down?
Claim 1 (independent) breaks into three enforceable pillars
Claim 1 defines a capsule with both immediate and delayed components, then requires performance by a defined in vitro dissolution test.
Pillar A: immediate release antibiotic in compressed minitablets
- “Immediate release first dosage composition”
- Form: compressed minitablets
- Contains: an antibiotic (composition type open-ended; later dependent claims narrow examples)
Pillar B: delayed release PPI in compressed minitablets with coating
- “Delayed release second dosage composition”
- Form: compressed minitablets
- Contains: a proton pump inhibitor
- Plus: a coating (coating is functional because it is tied to dissolution release profile)
Pillar C: basket dissolution profile is a claim-limiting performance test
The PPI minitablets must meet a two-stage dissolution profile in a basket apparatus:
- Acid stage: 900 mL of 0.1N HCl at 100 rpm
- PPI release: ≤ 10% by weight in 120 minutes
- Buffer stage: then 900 mL phosphate buffer pH 6.8 at 100 rpm after the acid stage
- PPI release: ≥ 75% by weight in 45 minutes
Legal consequence: Infringement analysis for Claim 1 turns heavily on whether an accused product’s PPI-containing delayed component, when tested in the specified apparatus and conditions, meets both thresholds. Even with different coating chemistries, a product can still fall within scope if dissolution performance meets the claim-defined release window.
Claim 1’s structural takeaways for product design
- It is a capsule with at least two dosage compositions (immediate and delayed).
- Both compositions are compressed minitablets, not granules or powders.
- The delayed PPI component is functionally tied to acid inhibition of release and rapid buffer release.
- The claim does not require specific capsule architecture in Claim 1 (that appears in dependent claims), but it does require the capsule to contain both dosage compositions.
How do dependent claims narrow the commercial boundary (Claims 2 to 18)?
Coating delay duration
- Claim 2: coating delays PPI release from 120 to at least 240 minutes following oral administration.
- This adds an in vivo-orally framed timing limitation layered on top of in vitro dissolution.
Antibiotic and PPI species coverage
- Claim 3: first dosage composition includes amoxicillin.
- Claim 4: PPI is one of:
- omeprazole, pantoprazole, lansoprazole, ilaprazole, dexlansoprazole, esomeprazole, rabeprazole
- plus pharmaceutically acceptable salts/solvates or combinations
This makes the claim set broad across “-prazole” PPIs while still tethered to the compressed minitablet + coating + dissolution profile combination.
Time-delay agent as an additional design constraint
- Claim 5: delayed second dosage composition comprises a time delay agent.
- Claim 6: time delay agent is one of:
- sodium alginate
- glyceryl monostearate
- glyceryl distearate
- acrylic acids
- celluloses
- or combinations
This dependent layer helps the patentee argue coverage where coating systems rely on recognized retardants or matrix-formers.
Quantitative release windows beyond Claim 1
- Claim 7 adds additional dissolution-by-time performance bounds, aligned to oral administration:
- Antibiotic: ≥ 70% by weight released between 5 and 120 minutes
- PPI: ≥ 70% by weight released between 120 and 240 minutes
This expands enforceability from purely basket acid-to-buffer thresholds to broader release timing windows.
Specific combination product example and ratio
- Claim 8: capsule comprises amoxicillin + omeprazole.
- Claim 9: amoxicillin-to-omeprazole ratio is 20 to 40 by weight.
This is a meaningful commercial guardrail for fixed-dose combinations marketed as specific ratio products.
Excipients enumerated (Claims 10 to 16)
- Claim 10: first and second compositions further comprise typical excipients (filler, disintegrant, binder, surfactant, alkalizing agent, lubricant).
- Claims 11 to 16 enumerate specific options for each excipient class:
- Filler: lactose, cellulose, starch, calcium phosphates, calcium carbonate, sugar
- Disintegrant: croscarmellose sodium, carboxymethyl cellulose, sodium starch glycolate, crospovidone
- Binder: starch, cellulose, polyvinylpyrrolidone, xanthan gum, alginic acid, agar
- Surfactant: sodium lauryl sulphate; polyoxyethylene polyoxypropylene glycol; polyethylene glycol; polypropylene glycol; polymeric surfactant systems including polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol; macrogolglycerol hydroxystearate
- Alkalizing agent: meglumine, calcium carbonate, sodium sulfate, sodium bicarbonate
- Lubricant: magnesium stearate, silicon dioxide, talc, stearic acid, sodium stearyl fumarate, glyceryl behenate
These dependent claims are valuable for argument of formulation capture. Practically, they also provide a roadmap for how an applicant may tailor formulation choices and still remain inside the literal claim set.
Specific dose amounts (Claim 17)
- Claim 17: first composition 250 mg amoxicillin; second composition 10 mg omeprazole (or derivatives/salts/solvates).
This is the tightest formulation and strength anchor in the provided claim excerpt, and it defines a likely target product commercialized at those strengths.
Protective-layer architecture (Claim 18)
- Claim 18: second dosage composition comprises:
- outer protective layer
- enteric coating
- inner protective layer
This adds extra physical architecture beyond a generic “coating,” strengthening literal coverage for products with multi-layer enteric systems.
How do the method claims (Claims 19 and 20) extend enforceability?
Claim 19: regimen and condition
- Treating H. pylori by administering the capsule of Claim 1
- Frequency: three times a day
Claim 20: duration and eradication performance
- Treatment for at least 14 days
- Results: eradication rate > 84%
This is an effectiveness/clinical-response-limiting claim. For enforcement, it creates an evidentiary hook tied to performance outcomes.
Commercial impact: Even if a capsule is challenged on dissolution, the method claims create additional exposure for branded label regimens consistent with the claimed dosing schedule and duration, with the asserted eradication criterion.
Claim-to-landscape mapping: where the enforceable differentiator sits
Across many H. pylori fixed-dose regimens, overlap typically exists on:
- antibiotic selection
- PPI selection
- general delayed release (enteric coating concept)
- dual component therapy in a capsule or tablet
Patent 9,603,806’s differentiator is the combination of:
- compressed minitablets for both immediate and delayed components,
- defined basket dissolution thresholds (≤10% PPI in acid at 120 min; ≥75% in buffer at 45 min after acid),
- further release timing windows tied to 5-120 min antibiotic release and 120-240 min PPI release,
- and optionally specific excipient classes and architectures (outer/enteric/inner protective layers).
That combination is the legal moat because it can exclude near-designs that use delayed release but do not hit the exact acid-to-buffer dissolution profile, or do not use minitablets.
What does this mean for infringement strategy and design-around risk?
If you make a near product, Claim 1 dissolves the design surface into a measurable target
An accused product will be compared against:
- the PPI release during 0.1N HCl, 100 rpm, 900 mL, 120 min (must be ≤10% by weight), then
- the PPI release during pH 6.8 phosphate buffer (must be ≥75% by weight within 45 min)
Design-around typically tries to avoid either:
- failing acid-stage release limits (too high release early), or
- preventing rapid buffer-stage release (too slow in buffer), or
- removing structural features such as compressed minitablets.
However, Claim 7 and Claim 2 add secondary timing boundaries, including oral timing delay and 120-240 min PPI release window, so “almost-right” dissolution may still land in dependent claims.
If you want to stay within the safe zone, the critical test is not label language
Label language and API selection matter (Claim 4 enumerates PPIs; Claim 3 and Claim 8 cover amoxicillin and amoxicillin/omeprazole), but the hardest-edged limitations are test-based.
Landscape implications for R&D and licensing
Likely competitive adjacency
The claim set is tailored to pharmaceutical development programs seeking:
- oral dual-release regimens for H. pylori
- improved spatial separation between antibiotic release and PPI release to match gastric conditions
- minitablet-based capsule technologies to control local dissolution behavior
Licensing leverage points
When evaluating freedom-to-operate for a product intended for H. pylori therapy:
- products meeting the Claim 1 dissolution and using minitablet formats create higher licensing pressure.
- products using different dosage forms (e.g., pellets without compressed minitablets, or monolithic tablets) may reduce risk if “compressed minitablets” is not met, but literal capture depends on claim construction.
Key claim elements checklist (for diligence)
Use this as a mapping grid for product characterization, formulation dossiers, and test protocols:
| Claim element |
What to verify in competitor/product files |
| Two compositions in one capsule |
Presence of immediate + delayed dosage units |
| Immediate unit format |
“Compressed minitablets” for antibiotic fraction |
| Delayed unit format |
“Compressed minitablets” for PPI fraction |
| PPI inhibition in acid |
≤10% by weight in 0.1N HCl (900 mL, 100 rpm) over 120 min (basket) |
| Buffer release requirement |
≥75% by weight in pH 6.8 phosphate buffer (900 mL, 100 rpm) within 45 min after acid stage |
| Oral delay |
Coating delays PPI release from 120 to at least 240 min (if pursuing Claim 2 layer) |
| Antibiotic release timing |
≥70% released between 5 and 120 min (Claim 7 layer) |
| PPI release timing |
≥70% released between 120 and 240 min (Claim 7 layer) |
| PPI identity |
Listed PPIs in Claim 4 (if checking literal identity) |
| Ratios and strengths |
250 mg amoxicillin / 10 mg omeprazole (Claim 17) and 20-40 wt ratio (Claim 9) |
| Enteric architecture |
Outer protective layer + enteric coating + inner protective layer (Claim 18) |
| Method regimen |
3x/day for at least 14 days and eradication >84% (Claims 19-20) |
What is the practical scope of coverage (in business terms)?
Breadth
- Broad antibiotic coverage at the independent level (any antibiotic) with examples later (amoxicillin).
- Broad PPI coverage across multiple -prazoles.
Narrowness
- Tight dissolution performance requirements tied to basket testing.
- Tight physical unit specification (compressed minitablets).
- Tight dosing architecture in dependent claims (multi-layer coating, specific excipients, dose strengths, ratio).
Net effect: The patent is broad in API selection but narrow in formulation architecture and measured performance.
Key Takeaways
- Claim 1 is the enforceable core: a capsule with immediate-release antibiotic compressed minitablets plus delayed-release PPI compressed minitablets whose basket dissolution meets an explicit acid-to-buffer release profile (≤10% at 120 min in 0.1N HCl; ≥75% at 45 min in pH 6.8 buffer after the acid stage).
- Dependent claims tighten commercial coverage through oral delay timing, specific PPI list, time-delay agent exemplars, explicit antibiotic release and PPI release windows, and multi-layer enteric architecture.
- Method claims extend exposure to H. pylori regimens at three times daily for at least 14 days with eradication rate >84%.
- For competitive diligence, the decisive question is whether a product hits the claim-defined dissolution thresholds using the same test framework, not only whether it uses amoxicillin and a -prazole.
FAQs
1) Does Claim 1 require a specific antibiotic?
No. Claim 1 requires an “antibiotic” generally; amoxicillin is covered in dependent claim territory (Claim 3 and Claim 8).
2) Is the delayed PPI limitation defined by ingredients or by performance?
Both, but the performance is claim-limiting: Claim 1 requires the delayed PPI minitablets meet the basket dissolution two-stage profile in acid then buffer.
3) Can a different PPI still infringe?
Yes. Claim 4 lists multiple PPIs (including omeprazole, pantoprazole, lansoprazole, ilaprazole, dexlansoprazole, esomeprazole, rabeprazole) and includes salts/solvates.
4) What is the fastest way to screen for risk across competitors?
Run a diligence mapping focused on whether their delayed PPI fraction is made of compressed minitablets and whether its dissolution matches the ≤10% acid-stage and ≥75% buffer-stage basket outcomes.
5) Do the method claims matter if a product is not marketed with the exact regimen?
They matter because Claims 19-20 define an administration method for H. pylori: three times daily for at least 14 days, with claimed eradication >84% tied to outcomes.
References
No citations were provided in the input for the patent text, prosecution history, or related US/global family documents; therefore, no sources are cited.
